China Approves IM19 CAR T for Later-Line Large B Cell Lymphoma

Company Beijing Imunopharm Event Type NMPA approval (China) Modality Autologous CD19 CAR T Asset Poji-ocel (IM19, Saibohua) Target CD19 Disease Area Relapsed or refractory large B-cell lymphoma Summary Previously missed November 5 event, confirmed by a company announcement and the regulator-linked Chinese announcement on November…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *